Therapeutic patents for cytomegalovirus

Bibliography

• GRIFFITHS PD, BABOONIAN CA: A prospective study of primary cytomegalovirus infection during pregnancy: final report. Brit. J. Obst. Gyn. (1984) 91(4):307–314.
   PubMedGoogle Scholar
• ROBACK JD: CMV and blood transfusions. Rev. Med. Vic (2002) 12(0211–219.
   PubMed Web of Science ®Google Scholar
• GRUNDY JE, LUI SF, SUPER M et al.: Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet (1988) 2(8603):132–135.
   PubMedGoogle Scholar
• LECHNER F, GUERO AL, KANTZANOU M, KLENERMAN P: Studies of human antiviral CD8+ lymphocytes using class I peptide tetramers. Rev Med. Vic (2001) 11(1):11–22.
   PubMed Web of Science ®Google Scholar
• RUBIN RH: The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA (1989) 261(24)3607–3609.
   Google Scholar
• COPE AV, SWENY P, SABIN C, REES L, GRIFFITHS PD, EMERY VC: Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. Med. Vic (1997) 52(2):200–205.
   Google Scholar
• EMERY VC, COPE AV, BOWEN EF, GOR D, GRIFFITHS PD: The dynamics of human cytomegalovirus replication in vivo. J. Exp. Med. (1999) 190(2):177–182.
   PubMed Web of Science ®Google Scholar
• EMERY VC, GRIFFITHS PD: Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. PNAS (2000) 97(14)8039–8044.
   Google Scholar
• •Calculation of the antiviral efficacy of existing antiviral compounds.
   Google Scholar
• BOWEN EF, EMERY VC, WILSON P et al.: Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis. AIDS (1998) 12(6):605–611.
   PubMedGoogle Scholar
• HUH, JABS DA, FORMAN MS, MARTIN BK et al: Comparison of cytomegalovirus (CMV) UL97 gene sequences in the blood and vitreous of patients with acquired immunodeficiency syndrome and CMV retinitis. J. Infect. Dis. (2002) 185(7):861–867.
   PubMedGoogle Scholar
• LIMAYE AP, COREY L, KOELLE DM, DAVIS CL, BOECKH M: Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet (2000) 356(9230):645–649.
   PubMed Web of Science ®Google Scholar
• CHOU S, MAROUSEK G, GUENTZEL S et al.: Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. Infect. Dis. (1997) 176(3):786–789. EMERY VC: Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med. Vic (2001) 11(2):83–86. Counterpoint to article below. HART GD, PAYA CV: Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev. Med. Vic (2001) 11(2):73–81. Debate article proposing that prophylaxis is superior to pre-emptive therapy. INSTITUTE OF MEDICINE: Vaccines for the 21st Century Stratton KR, Durch JS, Lawrence RS (Eds.), Nat. Acad. Press (2000). Cost-benefit analysis of preventing CMV disease.
   Google Scholar
• WHITLEY RJ, CLOUD G, GRUBER W et al.: Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a Phase II study. Nat. Inst. of Allergy and Infect. Dis. Col. Antiviral Study Group. Infect. Dis. (1997) 175(5):1080–1086.
   Google Scholar
• KIMBERLIN DG: Ganciclovir treatment of symptomatic congenital cytomegalovirus infections: results of a Phase III randomized trial.' Paediatrics (In press).
   Google Scholar
• KIM WR, BADLEY AD, WIESNER RH et al.: The economic impact of cytomegalovirus infection after liver transplantation. Transplantation (2000) 69(3):357–361.
   PubMed Web of Science ®Google Scholar
• LOWANCE D, NEUMAYER HH, LEGENDRE CM et al.: Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. Int. Valacyclovir Cytomegalovirus Prophylaxis Transplant. Study Group. N Eng. J. Med. (1999) 340(19):1462–1470.
   PubMed Web of Science ®Google Scholar
• •Strong evidence that graft rejection is caused by CMV.
   Google Scholar
• VALANTINE HA, GAO SZ, MENON SG et al: Impact of prophylactic immediate post-transplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation (1999) 100(1):61–66.
   PubMed Web of Science ®Google Scholar
• WAGNER JA, ROSS H, HUNTS et al: Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation (1995) 60(12):1473–1477.
   PubMedGoogle Scholar
• DE CLERCQ E, NAESENS L, DE BOLLE L, SCHOLS D, ZHANG Y, NEYTS J: Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med. Vic (2001) 11(6):381–395.
   PubMed Web of Science ®Google Scholar
• DOCKRELL DH, PAYA CV: Human herpesevirus-6 and -7 in transplantation. Rev. Med. VP: (2001) 11(1):23–36.
   Google Scholar
• GRIFFITHS PD: The 2001 Garrod lecture. The treatment of cytomegalovirus infection. Antimicrob. Chemother. (2002) 49(2):243–253.
   PubMedGoogle Scholar
• PRICHARD MN, PENFOLD ME, DUKE GM, SPAETE RR, KEMBLE GW: A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev Med. 17k (2001) 11(3):191–200.
   Google Scholar
• PLOTKIN SA, HIGGINS R, KURTZ JB et al.: Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation (1994) 58(11):1176–1178.
   PubMed Web of Science ®Google Scholar
• SNOECK R, ANDREI G, BODAGHI B et al.: 2-chloro-3-pyridin 3 yl 5,6,7,8-tetrahydroindolizine-l-carboxamide (CMV 423), a new lead compound for treatment of human cytomegalovirus infections. Antiviral Res. (2002) 55(3):413.
   PubMedGoogle Scholar
• WEBER 0, BENDER W, ECKENBERG P et al.: Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Res (2001) 49(3):179–189.
   Google Scholar
• MOCARSKI ES, COURCELE CT: Cytomegalovirus and their replication. In: Fields VP: (Volume 1). Knipe DM, Howley PM (Eds), Lippincott Williams and Wilkins. (2001) 2629–2674.
   Google Scholar
• WATHEN MW: Non-nucleoside inhibitors of herpesviruses. Rev Med. Vic (2002) 12(3):167–178.
   PubMed Web of Science ®Google Scholar
• ADLER H, MESSERLE M, KOSZINOWSKI UH: Cloning of herpesviral genomes as bacterial artificial chromosomes. Rev Med. Vit: (2003) 13:111–121.
   Google Scholar
• •Overview of methods used to correlate phenotype with genotype.
   Google Scholar
• BRIDEAU RJ, KNECHTEL ML, HUENG A et at Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpeseviruses. Antiviral Res. (2002) 54(1):19–28.
   PubMed Web of Science ®Google Scholar
• WELCH AR, WOODS AS, MCNALLY LM, COTTER RJ, GIBSON W: A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site. PNAS (1991)88(23):10792–10796.
   PubMedGoogle Scholar
• CHEN P, TSUGE H, ALMASSY RJ et al.: Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Cell(1996) 86(5):835–843.
   PubMedGoogle Scholar
• BATRA R, KHAYAT R, TONG L: Molecular mechanism for dimerization to regulate the catalytic activity of human cytomegalovirus protease. Nat. Strati. Biol (2001) 8(9):810–817.
   PubMedGoogle Scholar
• LOREGIAN A, MARSDEN HS, PALU G: Protein-protein interactions as targets for antiviral chemotherapy. Rev. Med. Vk (2002) 12(4):239–262.
   Google Scholar
• BOGNER E: Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev Med. Vir (2002) 12(2):115–127.
   PubMed Web of Science ®Google Scholar
• BUERGER I, REEFSCHLAEGER J, BENDER W et al: A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.' Vir. (2001) 75(19):9077–9086.
   PubMedGoogle Scholar
• KROSKY PM, UNDERWOOD MR, TURK SR et al.: Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. Vk (1998) 72(6):4721–4728.
   Google Scholar
• PART GS, ANDERS DG: Eleven loci-encoding trans-acting factors are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA replication. VP: (1993) 67(12):6979–6988.
   Google Scholar
• MURANYI W, HAAS J, WAGNER M, KROHNE G, KOSZINOWSKI UH: Cytomegalovirus recruitment of cellular kinases to dissolve the nuclear lamina. Science(2002) 297(5582):854–857.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS PD: Studies of viral co-factors forhuman immunodeficiency virus in vitro and in vivo. J. Gen. Vir. (1998) 79(Pt 2):213–220.
   PubMedGoogle Scholar
• STREBLOW DN, SODERBERG-NAUCLER C, VIEIRA J et al: The human cytomegalovirus chemokine receptor U528 mediates vascular smooth muscle cell migration. Cell (1999) 99(5):511–520.
   PubMed Web of Science ®Google Scholar
• PENFOLD ME, DAIRAGHI DJ, DUKE GM et al.: Cytomegalovirus encodes a potent a chemokine. PNAS (1999) 96(17):9839–9844.
   PubMedGoogle Scholar
• KOTENKO SV, SACCANI S, IZOTOVA LS, MIROCHNITCHENKO OV, PESTKA S: Human cytomegalovirus harbours its own unique IL-10 homolog (cmv1L-10). PNAS (2000) 97(4):1695–1700.
   PubMedGoogle Scholar
• BORTHWICK AD, EXALL AM, HALEY TM, JACKSON DL, MASON AM, WEINGARTEN GG: Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability. Bioorg. Med. Chem. Lett. (2002) 12(13):1719–1722.
   Google Scholar